Vemurafenib, dabrafenib, and encorafenib are BRAF inhibitors (BRAFi) approved by the US Food and Drug Administration (FDA) to treat patients with BRAFV600E-mutated metastatic melanomas [3]. Here, BRAF is linked to metastatic melanoma.